Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus b conjugate and hepatitis B vaccine
- Development stage
- Approved
- Lead developer
- MCM Vaccine Co
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Vaxelis** is a fully liquid, hexavalent pediatric combination vaccine developed as V419. It provides active immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive *Haemophilus influenzae* type b disease. The vaccine combines diphtheria and tetanus toxoids; five acellular *Bordetella pertussis* antigens; inactivated poliovirus types 1, 2, and 3; recombinant hepatitis B surface antigen; and *H. influenzae* type b polyribosylribitol phosphate conjugated to meningococcal outer-membrane protein. It is administered by intramuscular injection in infants and young children.
- Brand names
- Vaxelis
- Other names
- DTaP-HB-IPV-HibDTaP-IPV-Hib-HepBhexavalent diphtheria-tetanus-pertussis-poliomyelitis-Haemophilus influenzae type b-hepatitis B vaccine
02
Targets
Poliovirus capsid proteinsHBsAg (Hepatitis B surface antigen)PRN (Pertactin)FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)FIM2/3 (Fimbrial protein 2 and 3)
Beyond the preview
Go deeper on diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus b conjugate and hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus b conjugate and hepatitis B vaccine.